Navigation Links
FDA Approves Additional Dosage Strengths of Shire's ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
Date:1/3/2008

s of VYVANSE were decreased appetite, difficulty falling asleep, stomachache, and irritability.

Aggression, new abnormal thoughts/behaviors, mania, growth suppression, worsening of motion or verbal tics, and Tourette's syndrome have been associated with use of drugs of this type. Tell the doctor if your child has blurred vision while taking VYVANSE.

SHIRE PLC

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe. Shire believes that a carefully selected portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's website: http://www.shire.com

"SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

Statements included herein that are not historical facts are forward- looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Shire's results could be materially affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of pharmaceutical research; product development including, but not limited to, the successful development of JUVISTA(R) (Human TGFBeta3) and GA-GCB (velaglucerase alfa); manufacturing and
'/>"/>

SOURCE Shire plc
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. FDA Approves New Mechanism of Action Labeling for Ranexa(R)
2. FDA Approves Diovan(R) for Treatment of High Blood Pressure in Children
3. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) as the First Medication for Add-On Treatment of Major Depressive Disorder (MDD)
4. FDA Approves New SPRYCEL(R) (Dasatinib) Product Labeling for Patients with Chronic-Phase CML
5. FDA Approves Genzymes Renvela(TM) for Dialysis Patients
6. FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer
7. FDA Approves DORIBAX(TM) for the Treatment of Complicated Intra-Abdominal and Complicated Urinary Tract Infections
8. FDA Approves Administration of LEXIVA(R) with Lower Dose of Boosting Medication Ritonavir
9. FDA Approves New 300mg Loading Dose Tablet for PLAVIX(R) (clopidogrel bisulfate)
10. FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia
11. NJ Board of Pharmacy Approves Wedgewood Pharmacy Technician-Training Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)Alberta Centre for Advanced Micro Nano Technology Products (ACAMP) hosts, health & medical seminar, , EDMONTON, Dec. 4 /PRNewswire/ - Today ACAMP hosted a health & medical seminar, explaini
(Date:12/3/2009)DALLAS, Dec. 3 ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), today provided an update on its European commercial launch of MuGard, an FDA approved treatment for oral mucositis, a deb
(Date:12/3/2009)HOPKINTON, Mass., Dec. 3 Caliper Life Sciences, Inc. (Nasdaq: CALP ), a leading provider of tools and services for drug discovery and life sciences research, today introduced Living Image 4.0 softwa
(Date:12/2/2009)NEW YORK, Dec. 2 Reportlinker.com announces that a new market research report is available in its catalogue: ,, Carbondioxide Incubators - A Global Market Perspective ,, http://www.reportlinker.co
Breaking Biology Technology:Alberta companies delivering new products to the health & medical marketplace 2Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 2Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 3Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 4Caliper Life Sciences Launches Living Image(R) 4.0 Software 2Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 2Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 3Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 4
... to Host Investor Conference Call on Monday, May 1... EDT, NEW YORK, May 9 Keryx Biopharmaceuticals,I...focused on the,acquisition, development and commer...tical products for the treatment of life-threateni...oday announced its results,for the first quarter e...
...ND, Calif., May 9 (Nasdaq: WHRT, TSX:,WHT) Since ...y") has,aggressively pursued various financing alt...hrough equity financing transactions and corporate...At April 30, 2008, the,Company had cash and cash e...nt liabilities of approximately $2.6 million. On M...
..., Fla., May 9 The Cancer Research Alliance, an,or...ncer centers including,Moffitt Cancer Center, is a...power over cancer by stepping up and donating $1 t...h Father,s Day., The campaign, dubbed the "Infini...o activate Americans everywhere to take matters in...
Other Biology Technology:Keryx Biopharmaceuticals, Inc. Announces First Quarter 2008 Financial Results 2Keryx Biopharmaceuticals, Inc. Announces First Quarter 2008 Financial Results 3Keryx Biopharmaceuticals, Inc. Announces First Quarter 2008 Financial Results 4Keryx Biopharmaceuticals, Inc. Announces First Quarter 2008 Financial Results 5WorldHeart Reports an Event of Default Under the Note Issued to Abiomed, Resignation of One of Its Board of Directors, and Results of Shareholder Vote at Its Annual Shareholders' Meeting 2WorldHeart Reports an Event of Default Under the Note Issued to Abiomed, Resignation of One of Its Board of Directors, and Results of Shareholder Vote at Its Annual Shareholders' Meeting 3WorldHeart Reports an Event of Default Under the Note Issued to Abiomed, Resignation of One of Its Board of Directors, and Results of Shareholder Vote at Its Annual Shareholders' Meeting 4Moffitt Cancer Center Joins National Campaign To Implore Americans To Donate $1 To Accelerate Cancer Research 2
(Date:12/3/2009)Contents of this message: , , Preliminary Press Conference Topics, Last Call! Press Field Trip to California Academy of Sciences museum, Attention PIOs: Sending Press Releases to Fall meeting, N
(Date:12/3/2009)Grand Rapids, Mich. (Dec. 3, 2009) Van Andel Research Institute (VARI) researchers have determined precisely how the plant hormone abscisic acid (ABA) works at the molecular level to help plants re
(Date:12/3/2009)Forest dwellers must be included in the design of the upcoming forest deal at Copenhagen in order to avoid a humanitarian crisis, according to a scientist at the University of Leeds. , Writing today
Breaking Biology News(10 mins):AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 2AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 3AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 4AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 5AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 6VAI researchers find long awaited key to creating drought resistant crops 2VAI researchers find long awaited key to creating drought resistant crops 3Forest deal at Copenhagen must avoid creating 'carbon refugees' 2Patient Centered Primary Care Collaborative Stakeholders Come to Washington DC for July Working Meeting 49072 1Patient Centered Primary Care Collaborative Stakeholders Come to Washington DC for July Working Meeting 49072 2Patient Centered Primary Care Collaborative Stakeholders Come to Washington DC for July Working Meeting 49072 3Data Presented at Society of Nuclear Medicine 2009 Annual Meeting Supports Potential of Peregrines Cotara 28R 29 for the Treatment of Brain Cancer 12651 1Data Presented at Society of Nuclear Medicine 2009 Annual Meeting Supports Potential of Peregrines Cotara 28R 29 for the Treatment of Brain Cancer 12651 2Data Presented at Society of Nuclear Medicine 2009 Annual Meeting Supports Potential of Peregrines Cotara 28R 29 for the Treatment of Brain Cancer 12651 3Data Presented at Society of Nuclear Medicine 2009 Annual Meeting Supports Potential of Peregrines Cotara 28R 29 for the Treatment of Brain Cancer 12651 4Data Presented at Society of Nuclear Medicine 2009 Annual Meeting Supports Potential of Peregrines Cotara 28R 29 for the Treatment of Brain Cancer 12651 5Data Presented at Society of Nuclear Medicine 2009 Annual Meeting Supports Potential of Peregrines Cotara 28R 29 for the Treatment of Brain Cancer 12651 6Government of Canada supports research to help address medical isotope shortage 49067 1
...ne is an ongoing challenge to blood services world...akob Disease (vCJD), emerge. An update on the late...orm of Bovine Spongiform Encephalopathy (BSE), com... transmission through blood transfusion was presen...nsfusion Congress. At the "Safety in Transfusion M...
...rs have learned how a common fish found along the ...same time. , The study marks the first time that s...n between the part of a vertebrate,s brain that co... ear that hears sound. The researchers believe tha...n midshipman fish (Porichthys notatus ) -- a 6- to...
...ing chemicals called neurotransmitters. One of tho...mma amino butyric acid), shows up in unusually hig...a new study from Washington University School of M...ed metastatic neuroendocrine tumors, which include...ancers that spread to other parts of the body. The...
Other Biology News:New results validating Pall prion reduction filter disclosed at ISBT Congress 2New results validating Pall prion reduction filter disclosed at ISBT Congress 3How fish hear and make sounds at same time 2Neurotransmitters signal aggressive cancer, offer potential for early diagnosis 2Neurotransmitters signal aggressive cancer, offer potential for early diagnosis 3
...ccessories necessary for casting gels for mutation...phism analysis (SSCP) with the DCode universal mut... finger adaptor for use with an external chiller (....75 mm spacers, two 20-well 0.75 mm combs, and san...
...etry accessible to anyone in the lab. Novice and e...o Guavas on-demand cytometry systemsthe Guava Easy...ery compact for higher throughput, multi-color det...ute cell counts, 6 parameters (4 fluorescent color...
...ity of the BDTM LSR, the first UV benchtop analyze... BD LSR II has performance, capabilities, and flex... Free up your high-performance cell sorter by movi...the BD LSR II. The BD LSR II can be configured wit...
BD FACSArray bioanalyzer from BD Biosciences - Immunocytometry Systems
Biology Products: